EpiTherapeutics partnered with Abbott in a three-year research program to discover and develop small molecule inhibitors of epigenetic targets for cancer

Abbott Laboratories

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

EpiTherapeutics ApS

Denmark / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced